ABSTRACT T-type calcium channels (Ca V 3) play an important role in many physiological and pathological processes, including cancerogenesis. Ca V 3 channel blockers have been proposed as potential cancer treatments. Roscovitine, a trisubstituted purine, is a cyclin-dependent kinase (CDK) inhibitor that is currently undergoing phase II clinical trials as an anticancer drug and has been shown to affect calcium and potassium channel activity. Here, we investigate the effect of roscovitine on Ca V 3.1 channels. Ca V 3.1 channels were transiently expressed in human embryonic kidney 293 cells, and currents were recorded by using the whole-cell patch-clamp technique. Roscovitine blocks Ca V 3.1 channels with higher affinity for depolarized cells (EC 50 of 10 M), which is associated with a negative shift in the voltage dependence of closed-state inactivation. Enhanced inactivation is mediated by roscovitine-induced acceleration of closedstate inactivation and slowed recovery from inactivation. Small effects of roscovitine were also observed on T-channel deactivation and open-state inactivation, but neither could explain the inhibitory effect. Roscovitine inhibits Ca V 3.1 channels within the therapeutic range (10 -50 M) in part by stabilizing the closed-inactivated state. The ability of roscovitine to block multiple mediators of proliferation, including CDKs and Ca V 3.1 channels, may facilitate its anticancer properties.
Introduction
T-type calcium channels (Ca V 3) are low voltage-activated channels with fast-inactivation and slow-deactivation kinetics that consist of three family members Ca V 3.1 (␣ 1G ), Ca V 3.2 (␣ 1H ), and Ca V 3.3 (␣ 1I ) (Perez-Reyes, 2003) . Ca V 3 channels are widely distributed among different cell types including neurons, cardiomyocytes, and smooth and skeletal muscles (Perez-Reyes, 2003) . In spite of establishing many aspects of function and cell specificity, nicely reviewed by Edward PerezReyes (Perez-Reyes, 2003) , their role in many physiological and pathophysiological processes remains unclear. However, an emerging body of evidence suggests that Ca V 3 channels can participate in pathological processes such as chronic pain (Jagodic et al., 2008) and cancer cell proliferation (Gray and Macdonald, 2006; Lee et al., 2006; Heo et al., 2008; Lu et al., 2008; Taylor et al., 2008a,b) . These findings, in particular regarding the channels' role in cancer, have made Ca V 3 channels an attractive clinical target (Gray and Macdonald, 2006) .
Roscovitine is a trisubstituted purine, which initially was proposed as an anticancer therapy because of its blocking effect on cyclin-dependent kinases (CDKs) Fischer and Gianella-Borradori, 2003; WesierskaGadek et al., 2007) . This drug is also known as CYC202 and seliciclib and is currently undergoing phase II clinical trials as a treatment for non-small-cell lung cancer and nasopharyngeal cancer. Emerging evidence suggests that roscovitine may have additional targets involved with tumor development. For example, we have shown that roscovitine can also inhibit human ether-a-go-go related gene (HERG) potassium channel activity (Ganapathi et al., 2009) , and HERG channel block can reduce the growth of certain cancer types (Pardo et al., 2005) . Ca V 3 channels are potential targets for anticancer therapy (Gray and Macdonald, 2006) . Ca V 3.1 channels are expressed in many human cancer cell types including liver, ovarian, and breast cancers, and proliferation is reduced by inhibition of these channels by either down-regulation (short interfering RNA) or drug application (Lu et al., 2008; Taylor et al., 2008a; Li et al., 2009 Li et al., , 2011 . Through its unique effects on ion channels, roscovitine has provided critical insights into gating mechanisms and the treatment of disease (Buraei et al., 2005 (Buraei et al., , 2007 Cho and Meriney, 2006; Yarotskyy and Elmslie, 2007; Buraei and Elmslie, 2008; Ganapathi et al., 2009; Yarotskyy et al., 2009; Yazawa et al., 2011) , which motivated us to test the effect of roscovitine on Ca V 3.1 channels. We find that Ca V 3.1 channels are inhibited by roscovitine. This inhibition is potentiated by depolarized voltages so that at a membrane potential of Ϫ70 mV the EC 50 is 10 M, which is at the low end of the therapeutic range (10 -50 M) for roscovitine block of cancer cell proliferation Fischer and Gianella-Borradori, 2003; WesierskaGadek et al., 2007) . We conclude that the inhibition of Ca V 3.1 channels could provide a third anticancer mechanism for roscovitine in addition to CDK and HERG block, which will probably enhance the therapeutic efficacy of roscovitine as an anticancer drug.
Materials and Methods

HEK Cell Transfection.
We used either calcium phosphate precipitation (Yarotskyy and Elmslie, 2007) or Lipofectamine 2000 (Yarotskyy et al., 2010) to transfect HEK293 cells with Ca V 3.1 channels (cloned from rat pancreatic ␤ cells, a generous gift from Dr. Ming Li, Tulane University Medical School, New Orleans, LA; Genbank no. AF125161) (Zhuang et al., 2000) , which provided highly reproducible expression 24 to 48 h after transfection. HEK293 cells were maintained in standard Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum and 1% antibiotic-antimycotic mixtures at 37°C in a 5% CO 2 incubator. HEK293 cells were transfected by adding cDNA plasmids as follows: 11.5 g of ␣ 1G (Ca V 3.1), 2.15 g of simian virus 40 large T-antigen (to increase expression efficiency), and 1 g of green fluorescent protein (to visualize transfected cells). They were incubated at 5% CO 2 for 8 h after which the transfecting medium was replaced by the standard DMEM. The transfected cells were split the next day into 35-mm dishes that served as the recording chamber. Recordings were performed 24 to 48 h after transfection.
Measurement of Ionic Currents. Cells were voltage-clamped by using the whole-cell configuration of the patch-clamp technique. Pipettes were pulled from Schott 8250 glass (Garner Glass, Claremont, CA) on a Sutter P-97 puller (Sutter Instrument Company, Novato, CA). Currents were recorded by using an Axopatch 200A amplifier (Molecular Devices, Sunnyvale, CA) and digitized with an ITC-18 data acquisition interface (Instrutech Corporation, Port Washington, NY). Experiments were controlled by a Power Macintosh G3 computer (Apple Computer, Cupertino, CA) running S5 data acquisition software written by Dr. Stephen Ikeda (National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD). Leak current was subtracted online by using a ϪP/4 protocol. Recordings were carried out at room temperature, and the holding potential (HP) was Ϫ120 mV, unless otherwise stated. Some studies examined Ca V 3.1 current activated by an action potential wave form (AP) that was generated by using a series of voltage steps and ramps with the following values (HP ϭ Ϫ120 mV): Ϫ80 mV for 1 ms, Ϫ80 to 37 mV in 0.5 ms, 37 to 40 mV in 0.1 ms, 40 to 37 mV in 0.1 ms, 37 to Ϫ80 mV in 1.5 ms, and Ϫ80 mV at 11.5 ms. A 20-Hz 10-AP train was generated by using the same voltage changes except that the 1-ms step to Ϫ80 mV was removed and voltage between APs within the train was Ϫ120 mV. Whole-cell currents were digitized depending on voltage step duration at 50 kHz (up to 100 ms), 10 kHz (200 ms), and 4 kHz (2000 ms) after analog filtering at 1 to 10 kHz. Data Analysis. Data were analyzed by using IgorPro versions 5 and 6 (WaveMetrics, Lake Oswego, OR) run on a Macintosh computer. Percentage of inhibition was measured by comparing the steady-state drug effect to the average of current measured before [control (Cntl)] and after full recovery [washout (WO)]. Activation time constant ( Act ) was determined by fitting a single exponential function to the step current after a 0.3-ms delay (Buraei et al., 2007) . The effect of roscovitine on T-channel inactivation was measured by using either 100-or 1000-ms inactivating voltage steps followed by a 20-ms test step to Ϫ20 mV. The I/I max ratio for the current measured from the test step was plotted against inactivating voltage (either 100-or 1000-ms steps) and fitted by a single Boltzmann equation to yield half-maximal voltage (V 0.5 ), slope factor (k), and the magnitude of inactivation. Inactivation time constant ( Inact ) was determined by fitting a single exponential function from peak step current to the end of the step. The development of closed-state inactivation was determined by measuring the effect of increasing duration of voltage steps to Ϫ70 mV on a 20-ms step to Ϫ20 mV (Serrano et al., 1999 ) (see Fig. 6A ). The recovery from inactivation protocol used a 1000-ms inactivating step to either Ϫ20 or Ϫ70 mV followed by a 20-ms test step to Ϫ20 mV after an increasing recovery time at Ϫ120 mV. Group data were calculated as mean Ϯ S.D. A paired t test was used for within-cell comparisons. One-way analysis of variance with Tukey honestly significant difference post hoc test was used to test for differences among three or more independent groups.
Solutions. The internal pipette solution contained 104 mM Nmethyl-D-glucamine (NMG)-Cl, 14 mM creatine-PO 4 , 6 mM MgCl 2 , 10 mM NMG-HEPES, 5 mM Tris-ATP, 0.3 mM Tris-GTP, and 10 mM NMG-EGTA with osmolarity of 280 mOsM and pH 7.3. The external recording solution contained 30 mM BaCl 2 , 100 mM NMGCl, and 10 mM NMG-HEPES with osmolarity of 300 mOsM and pH 7.3. R-roscovitine (Rosc) was prepared as a 50 mM stock solution in dimethyl sulfoxide and stored at Ϫ30°C. All external solutions contained the same dimethyl sulfoxide concentration so that the roscovitine concentration was the sole variable when changing solutions. Test solutions were applied from a gravity-fed perfusion system that provided complete solution exchange within 1 to 2 s.
Chemicals. All experiments used Rosc (De Azevedo et al., 1997) from LC Labs (Woburn, MA). DMEM, fetal bovine serum, and 100ϫ antibiotic/antimycotic (penicillin, streptomycin, and amphotericin B) were from Invitrogen (Carlsbad, CA). Other chemicals were obtained from Sigma (St. Louis, MO).
Results
Roscovitine Blocks T-Type Channels. Roscovitine has provided surprising insights into ion channel gating mechanisms and disease treatment (Buraei et al., 2005 (Buraei et al., , 2007 Cho and Meriney, 2006; Yarotskyy and Elmslie, 2007; Buraei and Elmslie, 2008; Ganapathi et al., 2009; Yarotskyy et al., 2009; Yazawa et al., 2011) . Thus, we were interested in determining whether T-channels would be affected. Ca V 3.1 channels expressed in HEK293 cells were activated by using 15-ms depolarizing steps ranging from Ϫ100 to ϩ20 mV, followed by repolarization to Ϫ100 mV (Fig. 1) . Roscovitine (45 M) strongly blocked the current in a voltage-independent manner (Fig. 1, A-C) . Figure 1C shows no significant difference in the percentage of inhibition across all current-generating voltages, which suggests that open channel block is not a mechanism for inhibition. The activation versus voltage relationship was examined in more detail by plotting tail current amplitude (I Tail ) versus step voltage (Fig. 1D ), which showed a very small right shift induced by 45 M roscovitine. Single Boltzmann function fitting yielded V 0.5 for control ϭ Ϫ38.0 Ϯ 4.5 mV, roscovitine ϭ Ϫ36.7 Ϯ 4.4 mV, and washout ϭ Ϫ37.6 Ϯ 4.6 mV (n ϭ 9) (Fig. 1D ) and slope factor (k) .08 Ϯ 0.64, and 6.01 Ϯ 0.82 (n ϭ 9) for control, roscovitine, and washout, respectively (Fig. 1D) . The roscovitine-induced changes were very small (⌬V 0.5 ϭ 0.9 Ϯ 0.9 mV; ⌬k ϭ 0.38 Ϯ 0.35), but significantly different from control (n ϭ 9; p Ͻ 0.05 for both). It is very unlikely that these small changes in activation voltage parameters would have physiological significance.
Roscovitine Does Not Affect Activation but Slows Deactivation of Ca V 3.1 Channels. We have reported previously that roscovitine slowed Ca V 1.2 channel activation, which contributes to the inhibitory effect (Yarotskyy and Elmslie, 2007; Yarotskyy et al., 2009) . For that reason, we examined the effect of roscovitine on Ca V 3.1 channel activation speed by comparing Act determined by fitting step current onset with a single exponential function. We found no effect of roscovitine on Act at any Ca V 3.1 current-generating voltage. Indeed, normalized step currents were superimposed in control versus 45 M roscovitine (Supplemental Fig. 1 ).
The absence of an effect on Ca V 3.1 current activation suggests that the small shift in activation V 0.5 observed in Fig.  1D is induced by a different mechanism. Because there is precedent for roscovitine to slow calcium channel deactivation (Buraei et al., 2005 (Buraei et al., , 2007 , we measured the speed of Ca V 3.1 channel closing over voltages ranging from Ϫ50 to Ϫ160 mV. Ca V 3.1 current was activated by 10-ms steps to Ϫ10 mV followed by a 72-ms repolarizing (tail) step (Fig. 2 ). The tail current was fitted by a single exponential function to yield the deactivation time constant ( Deact ), which was plotted against tail voltage (Fig. 2C ). Roscovitine significantly increased Deact at voltages ranging from Ϫ140 to Ϫ50 mV (p Ͻ 0.05). The effect was small and can be better demonstrated by the roscovitine-induced change in Deact (% ⌬ Deact ) (Fig. 2D) . Qualitatively, this effect is similar to that of roscovitine on Ca V 2.1 and Ca V 2.2 channels (ϳ7-fold increase in Deact ) (Buraei et al., 2005 (Buraei et al., , 2007 , but the increase of Ca V 3.1 current Deact was small and did not exceed 20%. This small effect on Deact is likely to mediate the minor roscovitine-induced right shift in activation V 0.5 ( Fig. 1D ) and could possibly reduce the overall Ca V 3.1 current inhibition by a small amount.
Roscovitine Blocks Ca V 3.1 Channels in a DoseDependent Manner. To determine the dose-dependent effect of roscovitine, we tested the effect of 1, 10, 30, 45, and 100 M roscovitine on Ca V 3.1 current (Fig. 3) . Fractional block was plotted against roscovitine concentration and fitted by Hill's equation yielding EC 50 of 40.5 Ϯ 7.6 M and Hill's coefficient of 1.55 Ϯ 0.11 (n ϭ 5). This EC 50 was in the range obtained for Ca V 1.2 channels (Yarotskyy and Elmslie, 2007) . Some Ca V 3 channel blockers, such as mibefradil (McDonough and Bean, 1998), octanol (Eckle and Todorovic, 2010) , and T-type antagonist A2 (Uebele et al., 2009) , can preferentially affect inactivated channels. We determined whether roscovitine had apparent higher affinity at a more depolarized holding potential at which Ca V 3.1 channels inactivate. We found that a Ϫ70-mV holding potential significantly decreased the roscovitine EC 50 of 10.0 Ϯ 1.0 M, and Hill's coefficient of 1.22 Ϯ 0.15 compared with the results from HP Ϫ120 mV (Fig. 3D ). This result supports the idea that roscovitine preferentially affects inactivated channels.
Roscovitine Slows Open-State Inactivation. Based on the effect of holding potential on the dose-response relationship, we expected to observe a significant enhancement of inactivation by roscovitine. Using 100-ms voltage steps to inactivate Ca V 3.1 channels, we found that roscovitine had the opposite effect with a significant decrease of inactivation at voltages Ն Ϫ40 mV (Fig. 4 ). There was a small roscovitineinduced enhancement of inactivation, but only at Ϫ80 and Ϫ70 mV. The more widespread effect was a ϳ20% decrease of Fig. 4A ) that corresponded with a significant slowing of inactivation at voltages ϾϪ40 mV (Fig. 4 , B and C). Although decreased inactivation was unexpected, we realized that the reduced inactivation corresponded to currentgenerating voltages, whereas a small, but significant, enhancement of inactivation was observed at voltages hyperpolarized to channel activation. This suggested that roscovitine may enhance only closed-state inactivation, while slightly decreasing open-state inactivation.
Roscovitine Affects Closed-State Inactivation. The 4-fold reduction in roscovitine EC 50 with depolarized holding potential (Ϫ120 to Ϫ70 mV) supports the idea that the inactivated state is stabilized by roscovitine (Fig. 3) . Because holding potential changes generally affect closed-state (also called steady-state) inactivation, we tested the effect of longer voltage steps (1000 ms) (Fig. 5) , which hyperpolarized the inactivation V 0.5 by 20 mV from Ϫ52 mV for 100 ms to Ϫ73 mV for 1000 ms (Fig. 4A versus Fig. 5A ) so that much of the inactivation was now observed from closed Ca V 3.1 channels. Using this paradigm, 45 M roscovitine significantly leftshifted the inactivation versus voltage relationship ϳ10 mV to enhance inactivation at voltages around the resting potential (e.g., Ϫ70 mV) (Jones, 1989) . Boltzmann equation fits of the inactivation-voltage relationship yielded V 0.5 ϭ Ϫ73.4 Ϯ 2.8, Ϫ82.5 Ϯ 2.5, and Ϫ72.6 Ϯ 2.8 mV (n ϭ 6) for control, roscovitine, and washout, respectively (Fig. 5B) . The Boltzmann slope factor was also significantly increased, whereas maximum inactivation was significantly decreased for current generating voltages as observed for inactivation measured from 100-ms steps (Fig. 4A) . The enhancement of closed-state inactivation is reminiscent of the inhibitory effect of roscovitine on N-type channels (Buraei and Elmslie, 2008) . The decrease in open-state inactivation could have a potentiating effect on Ca V 3.1 current, but the enhancement of closed-state inactivation seems to dominate and increase roscovitine-induced inhibition of Ca V 3.1 channel activity.
Roscovitine Affects Inactivation Kinetics. The enhancement of closed-state inactivation by roscovitine could result from either an increased speed of inactivation, decreased recovery from inactivation, or both. We examined the time course for the development of closed-state inactivation , and washout (smaller gray trace). The repolarizing step was Ϫ70 mV after a depolarizing 10-ms step to Ϫ10 mV. The currents in A were normalized to peak tail current (B) to highlight the slower deactivation induced by roscovitine. C, the Deact was determined by fitting each tail current with a single exponential function. Deact was plotted against repolarizing (tail) voltage to gauge the speed of deactivation over voltages ranging from Ϫ50 to Ϫ160 mV. Roscovitine significantly increased Deact at voltages depolarized to Ϫ140 mV (black line; p Ͻ 0.05; n ϭ 9). Data are shown as mean Ϯ S.D. for control (gray circles), 45 M roscovitine (black squares), and washout (gray triangles). D, the percentage of change in Deact (%⌬ Deact ) induced by roscovitine (from C) was calculated from the average of control and washout data. The mean Ϯ S.D. are shown with the data significantly different from zero indicated by the line (p Ͻ 0.05). by examining the effect of increasing the Ϫ70-mV step duration (10 to 1900 ms) on current elicited at Ϫ20 mV (Fig. 6A) . The decrease of Ca V 3.1 current with step duration was fitted by single exponential function to yield the closedstate inactivation time constant ( CSI ) at Ϫ70 mV (Fig. 6 , B and C) and fractional current remaining at the end of the 1900-ms step [steady-state current (I SS )] (Fig. 6D) . Roscovitine (45 M) significantly decreased CSI by 184 ms (24%; p Ͻ 0.05; n ϭ 5; Fig. 6C ) and I SS by 0.14 (52%; p Ͻ 0.05; Fig. 6D ) relative to the averaged control and washout values ( CSI ϭ 751 ms; I SS ϭ 0.26). These results show that roscovitine enhances closed-state inactivation by speeding entry into the inactivated state.
The recovery from inactivation was investigated by using 1000-ms inactivating steps (Ϫ20 mV) to inactivate Ca V 3.1 channels and short test steps to Ϫ20 mV of increasing time from the inactivating step to measure the recovery of current (Fig. 7A) . The recovery voltage was Ϫ120 mV. We found that 45 M roscovitine significantly slowed recovery from inactivation (Fig. 7, A and B) . The recovery time course was best fit by using a double exponential function, which yielded fast and slow (Fig. 7B) . Roscovitine (45 M) doubled fast from 121 Ϯ 36 and 131 Ϯ 21 ms for control and washout, respectively, to 257 Ϯ 89 ms (p Ͻ 0.05; n ϭ 5), and slow was nearly doubled to 1181 Ϯ 227 ms from 652 Ϯ 111 and 695 Ϯ 100 ms (n ϭ 5; p Ͻ 0.05) in control and washout, respectively. The relative amplitude of the slow recovery component was increased from 56% (average control and washout) to 71% of the total (not significant; p ϭ 0.08). Thus, the enhancement of closed-state inactivation could result from slowed recovery from inactivation as well as faster inactivation. This was further investigated by measuring the recovery from inactivation after 1000-ms steps to Ϫ70 mV (Fig. 7C) . As observed after Ϫ20-mV steps, 45 M roscovitine significantly slowed the recovery from inactivation generated by Ϫ70-mV steps (Fig. 7D) . Thus, recovery from closed-state inactivation is slowed by roscovitine. One difference was that the recovery was well described by a single exponential equation with the recovery in between the fast and slow measured after the Ϫ20-mV step. The expectation was that the values would be similar because the recovery voltage was Ϫ120 mV for both data sets. However, it is clear that a slow component of recovery exists after the Ϫ70-mV step because the amplitude A, open-state inactivation was investigated by using a voltage protocol consisting of 100-ms inactivating steps to voltages (V Inact ) ranging from Ϫ120 to 40 mV followed by 20-ms postpulse to Ϫ20 mV to assess channel availability. The postpulse current was normalized to that at Ϫ120 mV (I/I Max ) and plotted versus V Inact in Cntl (gray circle), 45 M Rosc (black square), and upon WO (gray triangle) (n ϭ 6). The smooth lines are fits to the inactivation data using the Boltzmann equation, which yielded V 0.5 ϭ Ϫ53.8, Ϫ53.7, and Ϫ52.6 mV, slope factor ϭ Ϫ7.4, Ϫ8.7, and Ϫ7.4, and maximum inactivation ϭ 0.91, 0.85, and 0.90 for control, 45 M roscovitine, and washout, respectively. Roscovitine significantly increased inactivation at Ϫ80 and Ϫ70 mV, but significantly decreased inactivation at voltages ՆϪ40 mV as indicated by the lines and asterisk (p Ͻ 0.05). B, the inactivating component of the current was measured by fitting a single exponential equation to current elicited by V Inact . The Inact is plotted versus V Inact for control, 45 M roscovitine, and washout. See Fig. 3A for a representative single exponential fit to inactivation over a 100-ms voltage step. The symbols have the same meaning as in A. Inact in roscovitine was significantly larger than control and washout for voltages Ն Ϫ30 mV as indicated by the line and asterisk. C, Inact in control and washout was averaged and used to determine the percentage change induced by 45 M roscovitine (from the data in B). The percentage change in Inact (%⌬V Inact ) is plotted versus V Inact . The line and asterisk indicate data significantly different from zero (p Ͻ 0.05).
Fig. 5.
Roscovitine enhances closed-state inactivation. A, for this study the voltage protocol was similar to that described in Fig. 4 except that the V Inact range was from Ϫ140 to 0 mV and the duration was 1000 ms. The postpulse current was normalized to that at Ϫ140 mV (I/I Max ) and plotted against V Inact for Cntl (gray circles), 45 M Rosc (black squares), and WO (gray triangles). The smooth lines are single Boltzmann function fits, which yielded V 0.5 ϭ Ϫ73.5, Ϫ82.7, and Ϫ73.1 mV and slope factor ϭ Ϫ7.6, Ϫ10.7, and Ϫ8.1 for control, roscovitine, and washout, respectively. Roscovitine significantly increased inactivation at voltages from Ϫ120 to Ϫ40 mV, but significantly decreased inactivation at voltage ϾϪ50 mV (p Ͻ 0.05). B, Boltzmann fitting parameters were averaged from the six cells used to generate A and shows the significant roscovitine-induced decrease in V 0.5 (left), increase in slope factor (center), and decrease in maximum inactivation (right) ‫,ء(‬ p Ͻ 0.05). Roscovitine data are shown in the black bars (R), and control (C) and washout (W) are shown in gray bars.
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at ASPET Journals on April 19, 2017 jpet.aspetjournals.org of the single exponential function reaches only 93% (p Ͻ 0.05) of the maximum recovery observed at 15 s (Fig. 7C) . The relatively small magnitude of the slow component (7% for Ϫ70 mV versus 56% for Ϫ20-mV steps) is the likely reason it was not well described by our exponential fitting. Most importantly, our data clearly show that the enhancement of roscovitine-induced inhibition at Ϫ70 mV results from accelerated entry into and slowed recovery from closed-state inactivation.
Physiological Impact of Roscovitine. Based on our voltage step data, we speculated that the dominant effect of roscovitine would be inhibition of physiologically activated current. However, deactivation kinetics critically shape Ca 2ϩ influx through action potential-activated Ca V channels (Llinás et al., 1981 (Llinás et al., , 1982 Buraei et al., 2005) , and roscovitine significantly slows Ca V 3.1 channel deactivation, which could potentially offset inhibition. Thus, we determined the effect of 45 M roscovitine on Ca V 3.1 current activated by a 2-ms AP (Fig. 8) . As predicted, roscovitine-induced inhibition dominated with a 53 Ϯ 4% inhibition of charge influx via Ca V 3.1 channels (Fig. 8C) . Compared with the 53 Ϯ 6% inhibition of step current by 45 M roscovitine (HP Ϫ120 mV; Fig. 3D ), it seems that slowed deactivation has little or no effect on the roscovitine-induced inhibition of AP-activated Ca V 3.1 current.
A separate issue involves the effect of roscovitine on reducing open-state inactivation. We wanted to determine whether this reduction would have an impact on AP-activated current, which was accomplished by examining the effect of 45 M roscovitine on Ca V 3.1 currents generated during a 10-AP, 20-Hz train (Fig. 9) . Under control conditions, Ca V 3.1 current decreased with each AP within the train as expected for accumulated inactivation (termed accommodation; Fig. 9 , A, B, and D), and roscovitine significantly enhanced accommodation over this 10-AP train (Fig. 9D) . As a result, roscovitine-induced inhibition was significantly increased from the first to the 10th AP within the train (Fig. 9, C and E) . Thus, the roscovitine-induced reduction of open-state inactivation has little or no effect and is dominated by slowed recovery from inactivation to increase inhibition during the AP train.
Discussion
We have found that roscovitine blocks Ca V 3.1 channels in a dose-dependent and holding potential-dependent manner. Depolarizing the holding potential from Ϫ120 to Ϫ70 mV decreased the EC 50 by 4-fold. Given that more than 50% of the channels are inactivated at the Ϫ70-mV holding potential, we tested the idea that roscovitine enhanced Ca V 3.1 channel inactivation. We were surprised to find that inactivation measured from current-generating voltages was slowed by roscovitine to yield a small, but significant, decrease of inactivation. Thus, open-state inactivation was not enhanced by roscovitine. However, longer voltage steps (1000 ms) increased inactivation from closed states, which was significantly enhanced by roscovitine. The development of closed-state inactivation was accelerated by roscovitine, whereas recovery from inactivation was slowed. Thus, increased occupancy of closed-state inactivation is a major mechanism by which roscovitine inhibits T-channel activity.
Roscovitine Inhibits Ca V 3.1 Current by Preferentially Affecting Inactivated Channels. We have previously shown that roscovitine-induced inhibition of Ca V 2.2 and Ca V 1.2 calcium channels was associated with enhanced voltage-dependent inactivation (Yarotskyy and Elmslie, 2007; Buraei and Elmslie, 2008) . For Ca V 2.2 channels, the roscovitine effect resulted from enhanced closed-state inactivation (Buraei and Elmslie, 2008) , whereas Ca V 1.2 channel open-state inactivation was selectively affected by roscovitine (Yarotskyy and Elmslie, 2007) . Like the Ca V 2.2 channel, roscovitine-induced Ca V 3.1 channel inhibition was enhanced at depolarized holding potentials that were associated with a 10-mV left shift in the Ca V 3.1 channel closed-state inactivation versus voltage relationship. This enhancement results from roscovitine speeding the development of closed-state inactivation and slowing the recovery from inactivation. The acceleration of closed-state inactivation is in stark contrast to the significant slowing of open-state inactivation, which mediated a small, but significant, decrease of open-state inactivation. Thus, roscovitine demonstrates that open-and closedstate inactivation can be differentially modulated in Ca V 3.1 channels, which may have clinical benefits. For Ca V 1.2 channels, the preferential enhancement of closed-state inactivation by dihydropyridine antagonists (e.g., nifedipine or amlodipine) makes them potent antihypertensive drugs without negative cardiac effects (e.g., negative ionotropy or bradycardia) (Elmslie, 2004) .
Our data show that the recovery from inactivation after 1-s Fig. 6 . Roscovitine speeds the development of closed-state inactivation. A, the voltage protocol to investigate the development of inactivation at voltages hyperpolarized to channel activation consisted of two stimuli, prepulse (pre) and postpulse (post), to Ϫ20 mV that bracketed a Ϫ70-mV step with duration varying from 10 to 1900 ms. B, the postpulse to prepulse current ratio (I Post /I Pre ) was plotted against the inactivating step duration, and the data were fitted by single exponential function to yield the time constant of CSI and residual I SS . Symbols have the same meaning as in Fig. 5 (n ϭ 5). C, roscovitine significantly decreased CSI (R; 45 M), compared with control (C) and WO. D, I SS was significantly decreased in 45 M roscovitine (R) compared with control (C) and WO (n ϭ 5; p Ͻ 0.05).
Yarotskyy and Elmslie
at ASPET Journals on April 19, 2017 jpet.aspetjournals.org steps to Ϫ20 mV was best fit by a double exponential equation in both control and roscovitine supporting multiple components. It is tempting to relate the two recovery components to open-state (fast recovery) and closed-state (slow recovery) inactivation. However, previous work using Ca V 3.2 channels demonstrated that recovery was well described by a single exponential process and the time constant was similar if inactivation occurred from either the open or closed state (Serrano et al., 1999) , which supports a common recovery pathway for these inactivation processes. Serrano et al. (1999) used short (60 ms) steps to inactivate Ca V 3.2 channels from the open state, whereas our step duration was 1 s for studying recovery kinetics. Our measurement of recovery from closed-state inactivation (1 s at Ϫ70 mV) clearly had multiple components with the majority of current (93%) recovering by 2.2 s at Ϫ120 mV, but full recovery was achieved only within the 15-s interval between sweeps at Ϫ120 mV. Unfortunately, this slow component (7%) was too small for an Fig. 7 . Roscovitine slows the recovery from inactivation. A, inactivation was induced by a 1000-ms step to Ϫ20 mV followed by steps to Ϫ120 mV varying from 10 to 1000 ms and a 20-ms postpulse to Ϫ20 mV to assess channel availability. Tail currents after the postpulse were removed to more clearly illustrate the recovery from inactivation for control (top) and in 45 M roscovitine (bottom). B, postpulse currents were normalized to the peak current from the inactivating step and plotted versus recovery time at Ϫ120 mV to show the time course for recovery from inactivation for control (gray circles), 45 M roscovitine (black squares), and washout (gray triangles) (n ϭ 5). The 15-s interval between sweeps provided full recovery from inactivation so that was included as the maximum recovery point. The smooth lines are double exponential function fits that yielded fast ϭ 118, 246, and 129 ms, and slow ϭ 593, 1074, and 691 ms for control, 45 M roscovitine, and washout, respectively. The amplitude of slow component relative to the fast recovery component (A slow /A fast ) was 1.4, 3.3, and 1.3 for control, roscovitine and washout, respectively. C, the recovery from closed-state inactivation was investigated by using a triple pulse protocol where 15-ms steps to Ϫ20 mV bracketed a 1000-ms step to Ϫ70 mV. For the I/I Max ratio, I Max was measured during the prepulse (before the Ϫ70-mV step), and I was measured from the postpulse (after the Ϫ70-mV step). The interval between sweeps was 15 s, which provided full recovery from inactivation. The smooth lines are single exponential fits to the data with ϭ 402, 609, and 409 ms for control, 45 M roscovitine and washout, respectively. The fractional amplitude of the recovery component was 0.59, 0.72, and 0.58 for control, roscovitine, and washout, respectively. The recovery at 2200 ms was 95, 92, and 92% of the maximal value (at 15 s) for control, roscovitine, and washout, respectively. D, the recovery after 1000-ms steps to Ϫ70 mV was averaged from eight cells. The gray bars show control (C) and washout (W) data, and the black bar shows data in 45 M roscovitine (R). Data are presented as mean Ϯ S.D. ‫,ء(‬ p Ͻ 0.05).
Fig. 8.
Roscovitine inhibits physiologically activated Ca V 3.1 current. A, Ca V 3.1 current was elicited by a 2-ms AP that ranged from Ϫ80 to ϩ40 mV. The holding potential was Ϫ120 mV, and the voltage was Ϫ80 mV for 1 ms before the start of the AP, which was too short to inactivate Ca V 3.1 channels. Rosc (45 M; black trace) inhibited the current relative to that of Cntl and WO (gray trace). B, Ca V 3.1 current was integrated from the onset of inward current to the end of the record (12 ms) to determine the charge influx (pC). Roscovitine (45 M) was applied as indicated by the black bar, and the interval between sweeps was 5 s. C, the mean Ϯ S.D. percentage of inhibition induced by 45 M roscovitine is shown (p Ͻ 0.05). The control value for calculating inhibition was the average of current before and upon recovery from roscovitine. jpet.aspetjournals.org accurate determination of the time course. It has long been recognized that Ca V 3 channels can recover from inactivation with multiple components and the slower recovery component can be increased with longer step durations (Bossu and Feltz, 1986; Herrington and Lingle, 1992) . Thus, the slow recovery component may correspond to a slow inactivation state for which occupancy requires longer and stronger depolarization. It is noteworthy that roscovitine significantly slowed recovery to contribute to the enhancement of closedstate inactivation and, thus, inhibition. One concern was how the multiple effects of roscovitine on Ca V 3.1 channels would affect physiologically activated current. Although our data strongly support the dominance of inhibition for Ca V 3.1 current activated by voltage steps, deactivation kinetics play an important role in determining Ca 2ϩ influx via action potential-activated Ca V channels (Lliná s et al., 1981 (Lliná s et al., , 1982 Buraei et al., 2005) . Because roscovitine significantly slowed Ca V 3.1 channel deactivation, we wanted to determine whether this had a measureable impact. However, there was no difference between the roscovitine-induced inhibition of Ca V 3.1 step current versus APactivated charge influx. Thus, slowed deactivation was probably too small to significantly affect inhibition.
The differential effect of roscovitine on open-state versus closed-state inactivation could also have a physiological impact. Although the decrease of open-state inactivation is small, it is possible that this effect would be measureable under conditions where open-state inactivation dominates. One such condition could be an AP train, where open-state inactivation is expected to accumulate with each pulse. In our test, we used Ϫ120 mV as the interpulse potential to limit the potential impact of closed-state inactivation. However, roscovitine still increased inhibition during the AP train so that current during the 10th pulse was significantly smaller than that of the first pulse. This increase is probably the result of the slowed recovery from inactivation induced by roscovitine. Even though open-state inactivation is reduced, the recovery from open-state inactivation at Ϫ120 mV is slowed by roscovitine, and it is this slowed recovery that enhances inhibition during the AP train. Does Closed-State Inactivation Fully Explain Roscovitine-Induced Inhibition? Many T-channel antagonists show enhanced block at depolarized holding potentials, including mibefradil (McDonough and Bean, 1998; Martin et al., 2000) , octanol (Eckle and Todorovic, 2010), and T-type antagonist A2 (Uebele et al., 2009 ). However, significant block of Ca V 3 current at holding potentials that maximally recover Ca V 3 channel inactivation suggests that closed channel block can also occur, but with lower affinity (McDonough and Bean, 1998) . This seems to be the case with roscovitine as well. We observed 50% inhibition at Ϫ120 mV induced by 45 M roscovitine. Although this concentration left-shifted the inactivation-voltage relationship 10 mV (1000-ms steps), maximal recovery from inactivation was still achieved at Ϫ120 mV (Fig. 5A) . Thus, it seems that closed Ca V 3.1 channels are sensitive to block by roscovitine, Fig. 9 . Increased action potential frequency enhances roscovitine-induced inhibition of Ca V 3.1 current. A, currents were generated by a 20-Hz AP train (HP Ϫ120 mV) in Cntl (gray trace) and 45 M Rosc (black trace). For clarity, currents generated upon washout of roscovitine are not shown (but see B). The smooth lines are single exponential fits to the data in B. B, current induced by each AP was integrated over 15 ms and plotted versus the AP number within each train. The smooth lines are single exponential fits to the data. Data are shown in control (gray upward triangle), roscovitine (black square), and upon washout (gray downward triangle) from the same cell in A. C, the roscovitine-induced inhibition was calculated (from B) for each action potential generated current in the train. Note the increase in roscovitine-induced inhibition over the AP train. D, accommodation was calculated as the decrease in current from the first to the last AP in the train. The mean (Ϯ S.D.; n ϭ 5) percentage of accommodation is shown for control (C), 45 M roscovitine (R), and upon recovery (WO). ‫ء‬ indicates significant difference from control (average of C and WO; p Ͻ 0.05). E, the roscovitine-induced jpet.aspetjournals.org but this state has at least a 4-fold lower affinity for the drug than the closed inactivation state.
One surprise was that the enhancement of closed-state inactivation by roscovitine is common between Ca V 2.2 and Ca V 3.1 channels, but open-state inactivation of Ca V 1.2 channels is selectively enhanced. Sequence comparisons between the three Ca V gene families shows much closer homology between the Ca V 1 and Ca V 2 families (ϳ52%) compared with the Ca V 2 and Ca V 3 families (ϳ28%) (Catterall et al., 2005) . Based on this, it seems more likely that Ca V 2.2 channels would share a common mechanism with Ca V 1.2 channels than with Ca V 3.1 channels. Roscovitine reveals the potential for similar closed-state inactivation mechanisms between the distantly related Ca V 2.2 and Ca V 3.1 channels. However, block of closed channels distinguishes Ca V 3.1 channel, because no inhibition was observed at holding potentials from which Ca V 2.2 channels were fully recovered from closed-state inactivation (Buraei and Elmslie, 2008) .
Roscovitine Is a Promising Anticancer Drug that Exhibits Beneficial Polypharmacy. Roscovitine is undergoing phase II clinical trials as an anticancer drug based on its CDK blocking effect Hahntow et al., 2004; Benson et al., 2007; Wesierska-Gadek et al., 2007) . Until very recently the anticancer properties were solely linked to CDK block with a therapeutic window of 10 to 50 M Fischer and Gianella-Borradori, 2003; Hahntow et al., 2004) . We showed that roscovitine's anticancer effect may also involve potassium channel blockade (Ganapathi et al., 2009) . HERG potassium channels can regulate cancer cell proliferation, and HERG blockers have been shown to reduce proliferation and invasiveness (Arcangeli, 2005; Masi et al., 2005; Pardo et al., 2005; Raschi et al., 2008) . Thus, HERG blockers have been proposed as an adjuvant cancer therapy (Pillozzi et al., 2007; Raschi et al., 2008) . Roscovitine blocked HERG channels with an EC 50 of 27 M, which could complement the CDK inhibition to more potently suppress the cancer cell development. Here, we reveal a third potential anticancer activity of this drug, which is to inhibit calcium entry through Ca V 3.1 channels with an EC 50 of 10 M at the Ϫ70-mV holding potential (at the low end of the roscovitine therapeutic window). Although polypharmacy was once thought to be an undesirable property for a drug, more recent insights have revealed the important benefits of multiple drug actions in treating disease, and polypharmacy has gained new importance in the pharmaceutical industry (Hopkins, 2008; Howitz and Sinclair, 2008; Yang et al., 2008) .
Ca V 3 channels seem to support abnormal calcium entry to enhance the proliferation of cancer cells, and Ca V 3 channel blockers are promising anticancer drugs (Gray and Macdonald, 2006; Lee et al., 2006; Heo et al., 2008; Lu et al., 2008; Taylor et al., 2008a,b) . Roscovitine more potently blocks Ca V 3.1 channels in the closed inactivated state, which increases its affinity at more depolarized holding potentials. Changes in membrane potential that are controlled by potassium channel activity (e.g., HERG) seem to be critical in the control of cell proliferation by enhancing calcium entry and controlling cell volume (Pardo, 2004) . Roscovitine block of potassium channel activity would depolarize the cancer cell to increase Ca V 3.1 channel closed-state inactivation and enhance roscovitine inhibition of Ca V 3.1 channel activity. Thus, the polypharmacy action of roscovitine could have synergistic benefits. 
